Dianthus Therapeutics (87E) Stock Statistics & Valuation Metrics
Total Valuation
Dianthus Therapeutics has a market cap or net worth of EUR 4.34B. The enterprise value is EUR 4.21B.
- Market Cap
- EUR 4.34B
- Enterprise Value
- EUR 4.21B
Share Statistics
Dianthus Therapeutics has 56,312,714 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 56,312,714
- Owned by Insiders
- 0.15%
- Owned by Institutions
- 55.10%
Financial Efficiency
Dianthus Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -35.55%.
- Return on Equity (ROE)
- -0.33
- Return on Assets (ROA)
- -0.31
- Return on Invested Capital (ROIC)
- -35.55%
- Return on Capital Employed (ROCE)
- -0.36
- Revenue Per Employee
- 22.13K
- Profits Per Employee
- -1.76M
- Employee Count
- 92
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Dianthus Therapeutics is 2867.67. Dianthus Therapeutics’s PEG ratio is 22.85.
- PE Ratio
- 2867.67
- PS Ratio
- 1770.43
- PB Ratio
- 3.97
- Price to FCF
- -27.36
- Price to Operating Cash Flow
- -28.16
- PEG Ratio
- 22.85
Income Statement
In the last 12 months, Dianthus Therapeutics had revenue of 2.04M and earned -162.34M in profits. Earnings per share was -4.20.
- Revenue
- 2.04M
- Gross Profit
- 2.04M
- Operating Income
- -177.93M
- Pretax Income
- -162.34M
- Net Income
- -162.34M
- EBITDA
- -161.91M
- Earnings Per Share (EPS)
- -4.20
Cash Flow
In the last 12 months, operating cash flow was -175.15M and capital expenditures -697,000, giving a free cash flow of -175.85M billion.
- Operating Cash Flow
- -175.15M
- Free Cash Flow
- -175.85M
- Free Cash Flow per Share
- -3.07
Dividends & Yields
Dianthus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.65%
- Earnings Yield
- -0.81%
Stock Price Statistics
- Beta
- 0.09
- 52-Week Price Change
- 163.79%
- 50-Day Moving Average
- 79.64
- 200-Day Moving Average
- 75.00
- Relative Strength Index (RSI)
- 54.12
- Average Volume (3m)
- 69
Important Dates
Dianthus Therapeutics upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Dianthus Therapeutics as a current ratio of 13.32, with Debt / Equity ratio of 0.28%
- Current Ratio
- 13.32
- Quick Ratio
- 13.32
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.31
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Dianthus Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Dianthus Therapeutics EV to EBITDA ratio is -120.76, with an EV/FCF ratio of -27.05.
- EV to Sales
- 1750.39
- EV to EBITDA
- -120.76
- EV to Free Cash Flow
- -27.05
- EV to Operating Cash Flow
- -27.16
Balance Sheet
Dianthus Therapeutics has EUR 837.78M in cash and marketable securities with EUR 1.21M in debt, giving a net cash position of EUR 836.58M billion.
- Cash & Marketable Securities
- EUR 837.78M
- Total Debt
- EUR 1.21M
- Net Cash
- EUR 836.58M
- Net Cash Per Share
- EUR 14.86
- Tangible Book Value Per Share
- EUR 21.65
Margins
Gross margin is 97.20%, with operating margin of -8683.89%, and net profit margin of -1463.83%.
- Gross Margin
- 97.20%
- Operating Margin
- -8683.89%
- Pretax Margin
- -1463.83%
- Net Profit Margin
- -1463.83%
- EBITDA Margin
- -1449.52%
- EBIT Margin
- -1463.83%
Analyst Forecast
The average price target for Dianthus Therapeutics is EUR 125.87, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 125.87
- Price Target Upside
- 64.53% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 11
- Revenue Growth Forecast
- -17.89%
- EPS Growth Forecast
- -8.86%
Scores
- Smart Score
- 5
- AI Score
- ―
